The Effect of Bovine Thrombin, Thrombin Receptor Agonist Peptide-6 and Chitosan on Activating Platelet-Rich Plasma
DOI:
https://doi.org/10.12970/2311-1755.2014.02.02.3Keywords:
Platelet-rich plasma, bovine thrombin, chitosan, TRAP, growth factors.Abstract
In this study, the platelet-rich plasma (PRP) activation by bovine thrombin, thrombin receptor agonist peptide-6 (TRAP), and chitosan to become platelet-rich gel (PRG) was examined. In addition to measuring in vitro clotting times and clot retraction over time, platelet-derived growth factor (PDGF) and transforming growth factor β-1 (TGF-β1) generated by clot formation were also assayed. Rapid polymerization of PRP was observed when activated with bovine thrombin, followed by TRAP and chitosan. Bovine thrombin caused considerable clot retraction at 1, 2, 4 hours, but the clot retraction with different activators was similar at 24 hours. Although levels of TGF-β1 were similar for all activators used, greater concentration of PDGF was detected from PRG after TRAP treatment. It was concluded activating PRP with TRAP or chitosan was a safe alternative to bovine thrombin, resulting in excellent working time, significantly less clot retraction, and more growth factors compared to the currently available activator.
References
Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55: 1294-9. http://dx.doi.org/10.1016/S0278-2391(97)90187-7
Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 638-46. http://dx.doi.org/10.1016/S1079-2104(98)90029-4
Sanchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. Int J Oral Maxillofac Implants 2003; 18: 93-103.
Weibrich G, Kleis WK, Hafner G. Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit vs. PCCS PRP system. Int J Oral Maxillofac Implants 2002; 17: 184-90.
Carlson NE, Roach RB Jr. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc 2002; 133: 1383-6. http://dx.doi.org/10.14219/jada.archive.2002.0054
Ueda M, Yamada Y, Ozawa R, Okazaki Y. Clinical case reports of injectable tissue-engineered bone for alveolar augmentation with simultaneous implant placement. Int J Periodontics Restorative Dent 2005; 25: 129-37.
Sammartino G, Tia M, Marenzi G, di Lauro AE, D'Agostino E, Claudio PP. Use of autologous platelet-rich plasma (PRP) in periodontal defect treatment after extraction of impacted mandibular third molars. J Oral Maxillofac Surg 2005; 63: 766-70. http://dx.doi.org/10.1016/j.joms.2005.02.010
Belli E, Longo B, Balestra FM. Autogenous platelet-rich plasma in combination with bovine-derived hydroxyapatite xenograft for treatment of a cystic lesion of the jaw. J Craniofac Surg 2005; 16: 978-80. http://dx.doi.org/10.1097/01.scs.0000183469.93084.f3
Steigmann M, Garg AK. A comparative study of bilateral sinus lifts performed with platelet-rich plasma alone vs. alloplastic graft material reconstituted with blood. Implant Dent 2005; 14: 261-6. http://dx.doi.org/10.1097/01.id.0000177412.84225.05
Anitua E. The use of plasma-rich growth factors (PRGF) in oral surgery. Pract Proced Aesthet Dent 2001; 13: 487-93.
Okuda K, Kawase T, Momose M, Murata M, Saito Y, Suzuki H. Platelet-rich plasma contains high levels of platelet-derived growth factor and transforming growth factor-beta and modulates the proliferation of periodontally related cells in vitro. J Periodontol 2003; 74: 849-57. http://dx.doi.org/10.1902/jop.2003.74.6.849
Tischler M. Platelet rich plasma, the use of autologous growth factors to enhance bone and soft tissue grafts. N Y State Dent J 2002; 68: 22-4.
Jakse N, Tangl S, Gilli R, et al. Influence of PRP on autogenous sinus grafts: An experimental study on sheep. Clin Oral Implant Res 2003; 14: 578-83. http://dx.doi.org/10.1034/j.1600-0501.2003.00928.x
Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96. http://dx.doi.org/10.1097/00000658-200101000-00014
Landesberg R, Moses M, Karpatkin M. Risks of using platelet rich plasma gel. J Oral Maxillofac Surg 1998; 56: 1116-7. http://dx.doi.org/10.1016/S0278-2391(98)90286-5
Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost 1999; 82: 353-6.
Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001; 86: 298-307.
Shen EC, Chou TC, Gau CH, Tu HP, Chen YT, Fu E. Releasing growth factors from activated human platelets after chitosan stimulation: a possible bio-material for platelet-rich plasma preparation. Clin Oral Implants Res 2006; 17: 572-8. http://dx.doi.org/10.1111/j.1600-0501.2004.01241.x
Landesberg R, Roy M, Glickman RS. Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg 2000; 58: 297-300. http://dx.doi.org/10.1016/S0278-2391(00)90058-2
Landesberg R, Burke A, Pinsky D, Katz R, Vo J, Eisig SB, Lu HH. Activation of platelet-rich plasma using thrombin receptor agonist peptide. J Oral Maxillofac Surg 2005; 63: 529-35. http://dx.doi.org/10.1016/j.joms.2004.12.007
Andersen Henrik, Greenberg DL, Fujikawa Kazuo. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-93. http://dx.doi.org/10.1073/pnas.96.20.11189
Torres J, Tamimi F, Tresguerres IF, Alkhraisat MH, Khraisat A, Blanco L. Effect of combining platelet-rich plasma with anorganic bovine bone on vertical bone regeneration: early healing assessment in rabbit calvariae. Int J Oral Maxillofac Implants 2010; 25: 123-9.
Camarini ET, Zanoni JN, Leite PC, Boos FB. Use of biomaterials with or without platelet-rich plasma in postextraction sites: a microscopic study in dogs. Int J Oral Maxillofac Implants 2009; 24: 432-8.
Shi B, Zhou Y, Wang YN, Cheng XR. Alveolar ridge preservation prior to implant placement with surgical-grade calcium sulfate and platelet-rich plasma: a pilot study in a canine model. Int J Oral Maxillofac Implants 2007; 22: 656-65.
Torres J, Tresguerres I, Tamimi F, Clemente C, Niembro E, Blanco L. Influence of platelet-rich plasma on bone regeneration: a histomorphometric study in rabbit calvaria. Int J Oral Maxillofac Implants 2007; 22: 563-8.
Aghaloo TL, Le AD, Freymiller EG, Avera S, Shimizu K, Nishimura RD. Immunohistochemical analysis of cortical and cancellous bone after radiation and the effect of platelet-rich plasma on autogenous bone grafting. Int J Oral Maxillofac Implants 2006; 21: 535-42.
Carano RA, Filvaroff EH. Angiogenesis and bone repair. Drug Discov Today 2003; 8: 980-9. http://dx.doi.org/10.1016/S1359-6446(03)02866-6
Keramaris NC, Calori GM, Nikolaou VS, Schemitsch EH, Giannoudis PV. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 2008; 39 (Suppl 2): S45-57. http://dx.doi.org/10.1016/S0020-1383(08)70015-9
Marx RE. Discussion: Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg 2000; 58: 300-1. http://dx.doi.org/10.1016/S0278-2391(00)90059-4
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 2001; 10: 225-8. http://dx.doi.org/10.1097/00008505-200110000-00002
